123 related articles for article (PubMed ID: 36933845)
1. Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study.
Sapir E; Pfeffer R; Wygoda M; Purim O; Levy A; Corn B; Amitay Y; Ohana P; Gabizon A
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):64-73. PubMed ID: 36933845
[TBL] [Abstract][Full Text] [Related]
2. Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside.
Gabizon A; Shmeeda H; Tahover E; Kornev G; Patil Y; Amitay Y; Ohana P; Sapir E; Zalipsky S
Adv Drug Deliv Rev; 2020; 154-155():13-26. PubMed ID: 32777239
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Gabizon AA; Tahover E; Golan T; Geva R; Perets R; Amitay Y; Shmeeda H; Ohana P
Invest New Drugs; 2020 Oct; 38(5):1411-1420. PubMed ID: 31955309
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Golan T; Grenader T; Ohana P; Amitay Y; Shmeeda H; La-Beck NM; Tahover E; Berger R; Gabizon AA
Cancer Med; 2015 Oct; 4(10):1472-83. PubMed ID: 26172205
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
6. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy.
Wei X; Patil Y; Ohana P; Amitay Y; Shmeeda H; Gabizon A; Barenholz Y
Mol Pharm; 2017 Dec; 14(12):4339-4345. PubMed ID: 28045540
[TBL] [Abstract][Full Text] [Related]
8. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.
Amitay Y; Shmeeda H; Patil Y; Gorin J; Tzemach D; Mak L; Ohana P; Gabizon A
Pharm Res; 2016 Mar; 33(3):686-700. PubMed ID: 26572644
[TBL] [Abstract][Full Text] [Related]
10. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.
Gabizon A; Ohana P; Amitay Y; Gorin J; Tzemach D; Mak L; Shmeeda H
Cancer Drug Resist; 2021; 4(2):463-484. PubMed ID: 35582027
[No Abstract] [Full Text] [Related]
11. Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors.
Dorot S; Tankel J; Doviner V; Shmeeda H; Amitay Y; Ohana P; Dagan A; Ben-Haim M; Reissman P; Gabizon A
Cancer Chemother Pharmacol; 2022 Aug; 90(2):109-114. PubMed ID: 35802145
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak AR; Miller WH; Uy GL; Blotner S; Young AM; Higgins B; Chen LC; Gore L
Invest New Drugs; 2020 Aug; 38(4):1156-1165. PubMed ID: 31734832
[TBL] [Abstract][Full Text] [Related]
15. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.
Gnad-Vogt SU; Hofheinz RD; Saussele S; Kreil S; Willer A; Willeke F; Pilz L; Hehlmann R; Hochhaus A
Anticancer Drugs; 2005 Apr; 16(4):435-40. PubMed ID: 15746580
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Pugh TJ; Chen C; Rabinovitch R; Eckhardt SG; Rusthoven KE; Swing R; Raben D
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):521-6. PubMed ID: 20133082
[TBL] [Abstract][Full Text] [Related]
19. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin (Duomeisu
Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
